News ReleaseView printer-friendly version
Quidel to Present at the UBS 2008 Global Life Sciences Conference
SAN DIEGO--(BUSINESS WIRE)--Sept. 16, 2008--Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, today announced that it will present at the UBS 2008 Global Life Sciences Conference to be held at the Grand Hyatt Hotel in New York on September 22-25, 2008.
Caren Mason, President and Chief Executive Officer, will present on Monday, September 22, 2008 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time).
A webcast and audio archive of the presentation will be available via the Investor Relations section of the Company's Web site at www.quidel.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 90 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com, www.colorectal-test.com or www.flutest.com.
John M. Radak, Chief Financial Officer
Porter Novelli Life Sciences
SOURCE: Quidel Corporation